[1] Liu H, Li C, Shen C, et al. MiR-212-3p inhibits glioblastoma cell proliferation by targeting SGK3[J]. J Neurooncol, 2015, 122(3):431-439. [2] Hou M, Lai Y, He S, et al. SGK3(CISK)may induce tumor angiogenesis(Hypothesis)[J]. Oncol Lett, 2015, 10(1):23-26. [3] Wang Y, Zhou D, Chen S. SGK3 is an androgen-inducible kinase promoting prostate cancer cell proliferation through activation of p70 S6 kinase and up-regulation of cyclin D1[J]. Mol Endocrinol, 2014, 28(6):935-948. [4] Gasser JA, Inuzuka H, Lau AW, et al. SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer[J]. Mol Cell, 2014, 56(4):595-607. [5] 郭红艳, 孙晓杰, 刘秀财, 等. 蛋白激酶SGK3与乳腺癌临床病理相关性研究[J]. 现代预防医学, 2016, 43(6):1142-1145. [6] 郭红艳, 孙晓杰, 刘秀财, 等. 蛋白激酶SGK3过表达对乳腺癌细胞株MDA-MB-231影响的研究[J]. 中华肿瘤防治杂志, 2016, 23(24):1601-1606. [7] Hausmann S, Brandt E, Köchel C, et al. Loss of serum and glucocorticoid-regulated kinase 3(SGK3)does not affect proliferation and survival of multiple myeloma cell lines[J]. PLoS One, 2015, 10(4):e0122689. [8] Bago R, Sommer E, Castel P, et al. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth[J]. EMBO J, 2016, 35(17):1902-1922. [9] Liu M, Chen LL, Chan TH, et al. Serum and glucocorticoid kinase 3 at 8q13. 1 promotes cell proliferation and survival in hepatocellular carcinoma[J]. Hepatology, 2012, 55(6):1754-1765. [10] Scortegagna M, Lau E, Zhang T, et al. PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets[J]. Cancer Res, 2015, 75(7):1399-1412. [11] Xu J, Wan M, He Q, et al. SGK3 is associated with estrogen receptor expression in breast cancer[J]. Breast Cancer Res Treat, 2012, 134(2):531-541. [12] Sun XJ, Liu XC, Liu B, et al. Serum-and glucocorticoid-regulated protein kinase 3(SGK3)overexpression promotes tumor development and aggression in breast cancer cells[J]. ONCOL LETTERS, 2016, 12:437-444. [13] Bruhn MA, Pearson RB, Hannan RD, et al. AKT-independent PI3-K signaling in cancer-emerging role for SGK3[J]. Cancer Manag Res, 2013, 5:281-292. [14] Bruhn MA, Pearson RB, Hannan RD, Sheppard KE. Second AKT:the rise of SGK in cancer signaling[J]. Growth Factors, 2010, 28(6):394-408. [15] Wang Y, Zhou D, Phung S, et al. SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis[J]. Proc Natl Acad Sci U S A, 2017, 114(8):E1500-E1508. |